Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536
- PMID: 20145140
- DOI: 10.1158/0008-5472.CAN-09-2181
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536
Abstract
In most patients with chronic myeloid leukemia (CML), the disease can be kept under control using the BCR/ABL kinase inhibitor imatinib. Nevertheless, resistance or intolerance to imatinib and other BCR/ABL inhibitors may occur during therapy. Therefore, CML research is focusing on novel targets and targeted drugs. Polo-like kinase 1 (Plk1) is a serine/threonine kinase that plays an essential role in mitosis. In this study, we examined the expression of Plk1 in CML cells and its potential role as a therapeutic target. Plk1 was found to be expressed in phosphorylated form in the CML cell line K562 as well as in primary CML cells in all patients tested. Inhibition of BCR/ABL by imatinib or nilotinib (AMN107) led to decreased expression of the Plk1 protein in CML cells, suggesting that BCR/ABL promotes Plk1 generation. Silencing of Plk1 in CML cells by a small interfering RNA approach was followed by cell cycle arrest and apoptosis. Furthermore, the Plk1-targeting drug BI 2536 was found to inhibit proliferation of imatinib-sensitive and imatinib-resistant CML cells, including leukemic cells, carrying the T315 mutation of BCR/ABL with reasonable IC(50) values (1-50 nmol/L). The growth-inhibitory effects of BI 2536 on CML cells were found to be associated with cell cycle arrest and apoptosis. Moreover, BI 2536 was found to synergize with imatinib and nilotinib in producing growth inhibition in CML cells. In conclusion, Plk1 is expressed in CML cells and may represent a novel, interesting target in imatinib-sensitive and imatinib-resistant CML.
Similar articles
-
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.J Exp Clin Cancer Res. 2019 May 23;38(1):216. doi: 10.1186/s13046-019-1197-9. J Exp Clin Cancer Res. 2019. PMID: 31122263 Free PMC article.
-
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Clin Cancer Res. 2013 Jan 15;19(2):404-14. doi: 10.1158/1078-0432.CCR-12-2799. Epub 2012 Nov 30. Clin Cancer Res. 2013. PMID: 23204129 Free PMC article.
-
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Blood Cells Mol Dis. 2014. PMID: 24629639
-
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.Ann Intern Med. 2006 Dec 19;145(12):913-23. doi: 10.7326/0003-4819-145-12-200612190-00008. Ann Intern Med. 2006. PMID: 17179059 Review.
-
[Research advance on molecular genetics of CML blast crisis].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008. PMID: 18315935 Review. Chinese.
Cited by
-
The CINs of Polo-Like Kinase 1 in Cancer.Cancers (Basel). 2020 Oct 13;12(10):2953. doi: 10.3390/cancers12102953. Cancers (Basel). 2020. PMID: 33066048 Free PMC article. Review.
-
Molecular biology of chronic myeloid leukemia.Cancer Sci. 2012 Sep;103(9):1601-10. doi: 10.1111/j.1349-7006.2012.02346.x. Epub 2012 Jul 11. Cancer Sci. 2012. PMID: 22632137 Free PMC article. Review.
-
Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia.Leukemia. 2017 Sep;31(9):1962-1974. doi: 10.1038/leu.2016.377. Epub 2016 Dec 23. Leukemia. 2017. PMID: 28008177 Free PMC article.
-
Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892. Int J Mol Sci. 2022. PMID: 36142803 Free PMC article.
-
The transcription factor YY1 is a substrate for Polo-like kinase 1 at the G2/M transition of the cell cycle.PLoS One. 2011 Jan 6;6(1):e15928. doi: 10.1371/journal.pone.0015928. PLoS One. 2011. PMID: 21253604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous